Belite Bio finalizes phase 3 clinical trial plans for advanced dry AMD treatment with LBS-008
November 18th 2022LBS-008 is an orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt disease and dry age-related macular degeneration.
Read More
Targeting VEGF: The future is now
November 17th 2022Ophthalmologists have learned to optimize their use of traditional anti-VEGF therapies and are now incorporating newer therapies like brolucizumab for managing retinal diseases, and in the not-so-distant future they can look forward to gaining familiarity with faricimab and using a new delivery system for ranibizumab.
Read More
NeoLight launches ROP risk management software ROPCheck.com for pediatric ophthalmology space
November 17th 2022According to the company, ROP Check builds upon its pediatric retina screening portfolio, adding digital management (schedule, document, bill, and transfer) for treating patients with retinopathy of prematurity.
Read More
AEYE Health gains FDA clearance to screen diabetics to head off blindness
November 15th 2022The screening of diabetics for retinopathy has recently become reimbursable in the US, the company noted in its news release, and the approval comes after positive Phase 3 clinical trial earlier this year.
Read More
AI-empowered diagnostic retina scans can help prevent heart and kidney diseases
November 10th 2022Mediwhale, an AI diagnostics company, aims for FDA approvals to increase non-invasive, early detection to save lives. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment.
Read More
EP. 5: EyeCon 2022: Last chance to earn those end-of-year CME credits
November 10th 2022This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.
Read More
Apellis to submit 24-month phase 3 data to FDA for pegcetacoplan NDA for geographic atrophy
November 4th 2022According to Apellis Pharmaceuticals, the submission will be a Major Amendment to the NDA, extending the review period by three months with an expected PDUFA target action date in February.
Read More
RGX-314 continues to be well tolerated in 50 patients from Cohorts 1-3 with no drug-related serious adverse events. The Phase II trial will be expanded to include higher third dose level, with patients stratified by DRSS levels across cohorts and all receiving short-course prophylactic ocular steroids following RGX-314 administration.
Read More
EYP-1901: A look at DAVIO and PAVIA clinical trial updates
November 3rd 2022Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.
Read More
Private practice vs academics: What do young ophthalmologists need to know?
November 2nd 2022Nicole Bajic, MD, and Neel S. Vaidya, MD, MPH, share their insights from when they were at this crossroads. Learn more clinical pearls on topics like this and more at Real World Ophthalmology’s virtual conference, “Top 10 Things I Wish I Knew Sooner,” this Saturday, November 5.
Read More
Altris unveils artificial intelligence platform for automated OCT scans analysis
November 2nd 2022The company's AI cloud-based platform is available via a browser to any eye care professional in the world. The artificial intelligence algorithm was trained on millions of graphically labeled OCT scans collected from ophthalmic clinics.
Read More
KYS Vision: clinical outcomes of remote physiologic monitoring for chronic retinal conditions
November 1st 2022The study is one of the first clinical trials to validate the clinical utility of real-world remote physiologic monitoring using an on-demand vision-as-a-service extension to the specialty retina clinic to enable remote monitoring of patients with chronic diseases such as AMD, diabetic retinopathy, and other retinal conditions.
Read More